Gasmi, A.; Roubaud, G.; Dariane, C.; Barret, E.; Beauval, J.-B.; Brureau, L.; Créhange, G.; Fiard, G.; Fromont, G.; Gauthé, M.;
et al. Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. J. Clin. Med. 2022, 11, 160.
https://doi.org/10.3390/jcm11010160
AMA Style
Gasmi A, Roubaud G, Dariane C, Barret E, Beauval J-B, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M,
et al. Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. Journal of Clinical Medicine. 2022; 11(1):160.
https://doi.org/10.3390/jcm11010160
Chicago/Turabian Style
Gasmi, Anis, Guilhem Roubaud, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé,
and et al. 2022. "Overview of the Development and Use of Akt Inhibitors in Prostate Cancer" Journal of Clinical Medicine 11, no. 1: 160.
https://doi.org/10.3390/jcm11010160
APA Style
Gasmi, A., Roubaud, G., Dariane, C., Barret, E., Beauval, J.-B., Brureau, L., Créhange, G., Fiard, G., Fromont, G., Gauthé, M., Ruffion, A., Renard-Penna, R., Sargos, P., Rouprêt, M., Ploussard, G., & Mathieu, R.
(2022). Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. Journal of Clinical Medicine, 11(1), 160.
https://doi.org/10.3390/jcm11010160
